BCLI — Brainstorm Cell Therapeutics Share News
0.000.00%
Last trade - 00:00BrainStorm rises on deal with US FDA on study design for ALS therapy
Brief: BrainStorm Cell Therapeutics To Provide Update On NurOwn Program
Brief: BrainStorm Cell Therapeutics To Unveil Phase 3b NurOwn Trial Design
Brief: Brainstorm Cell Therapeutics Submits Special Protocol Assessment Request To FDA For Phase 3B Trial Of NurOwn In ALS
Brief: Brainstorm Granted Patents For Allogeneic Exosome Platform-Product In Neurological Disorder Treatments
Brief: Brainstorm Cell Therapeutics Inc- Are Exploring Various Strategies To Secure Necessary Funding
Brief: Brainstorm Cell Therapeutics Says FDA Meeting on NurOwn Provided A Clear Path For Planned Phase 3B Trial
Brief: BrainStorm Cell Therapeutics Announces In-Person Meeting with the FDA to Discuss Confirmatory Phase 3 Trial for NurOwn in ALS
U.S. STOCKS ON THE MOVE-LianBio, HCA, Nike
U.S. STOCKS ON THE MOVE-Coca-Cola, Verizon, RTX
Brainstorm Cell Therapeutics gains on plan to restructure, cut jobs
Brief: BrainStorm Cell To Cut About 30% Jobs
Brief: Brainstorm Cell Therapeutics To Meet With US FDA To Discuss Development Plan For NurOwn As A Treatment Of ALS
U.S. STOCKS ON THE MOVE-General Electric, Nike, Dell Technologies
U.S. STOCKS ON THE MOVE-Workday, Amazon, Accenture
BrainStorm hits record low after FDA panel votes against co's ALS therapy
U.S. STOCKS ON THE MOVE-Bolt Biotherapeutics, Sunnova, Jabil
U.S. STOCKS ON THE MOVE-Peloton, SPI Energy, Bionomics
BrainStorm slides after FDA panel votes against co's ALS therapy